在阿尔茨海默氏病的转基因模型中,Neurofabine-C的表观遗传调制和神经保护作用
Ivan Carrera1, Vinogran Naidoo1, Lola Corzo1
1EuroEspes Biomedical Research Center, International Center of Neuroscience and Genomic Medicine, 15165 Bergondo, Corunna, Spain.
Genes
|October 29, 2025
概括
神经纤维素-C是一种新的可可和法巴豆化合物,通过减少炎症和促进神经发生,有效地对抗神经退行. 这种神经保护剂在治疗神经炎症疾病方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 神经退行性疾病由于渐进的神经元损失和神经炎症而带来挑战.
- 可可黄具有抗氧化和抗炎功效.
- 法巴豆提取物增强多巴胺,并显示神经保护潜力.
研究的目的:
- 为了研究Neurofabine-C的协同神经保护作用,这种混合可可和法巴豆提取物.
- 分析Neurofabine-C对与炎症,新陈代谢和神经退行相关的大脑生物标志物的影响.
主要方法:
- 使用了三重转基因小鼠神经退行模型.
- 进行的Neurofabine-C治疗.
- 进行生物化学和免疫组织化学分析以获取生物分子数据.
主要成果:
- 神经纤维素-C可以预防神经元损失 (NeuN) 和减少神经炎症 (GFAP).
- 增加神经发生 (PAX6) 和调节的神经保护基因表达 (上调FOXO3,ATM,TRP73;下调HIF1α,APOE).
- 诱导了显著的表观遗传变化,包括染色质重塑,增加了DNA甲基化 (DNMT3A,5-甲基) 和减少了基因素脱乙烯化 (HDAC3).
结论:
- 神经纤维素-C显示出多方面的神经保护机制.
- 该化合物有效地减轻神经炎症并促进神经发生.
- 神经纤维素-C代表了神经退行性疾病的有希望的治疗候选者.
相关概念视频
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


